SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-291669
Filing Date
2023-12-08
Accepted
2023-12-08 16:05:35
Documents
13
Period of Report
2023-12-07
Items
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d636207d8k.htm   iXBRL 8-K 26727
2 EX-14.1 d636207dex141.htm EX-14.1 80435
  Complete submission text file 0001193125-23-291669.txt   253014

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dawn-20231207.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dawn-20231207_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dawn-20231207_pre.xml EX-101.PRE 11711
7 EXTRACTED XBRL INSTANCE DOCUMENT d636207d8k_htm.xml XML 3485
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

IRS No.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40431 | Film No.: 231475403
SIC: 2834 Pharmaceutical Preparations